First published: April 7, 2022
AmbioPharm is pleased to have played a role in recently published COVID-19 research, out of the Schmidtchen Lab of Lund University, by chemically synthesizing thrombin-derived C-terminal peptide (TCP-25). COVID-19 arises as a result of infection with the virus SARS-CoV-2 and an excessive inflammatory response can result. The research team has published “Experimental Model of Pulmonary Inflammation Induced by SARSCoV‑2 Spike Protein and Endotoxin” in ACS Pharmacology & Translational Science. The experimental model described could be used for analyses of the pathophysiological features of COVID-19 and for the development of new treatments and was primarily focused on pulmonary inflammation. TCP-25 is a peptide that is a part of innate immunity, an inborn defense system of an organism. TCP-25 plays a role in reducing infection-related inflammation, and in this model, acted as a lipopolysaccharide (LPS) scavenger and CD14 blocker, both of which play a role in COVID-19 induced acute respiratory distress syndrome (ARDS).
Access the article linked here: “Experimental Model of Pulmonary Inflammation Induced by SARSCoV‑2 Spike Protein and Endotoxin”